| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/23/2003 | CN1432015A Indazoles substituted with 1,1-dioxoisothiazolidine useful as inhibitors of cell proliferation |
| 07/23/2003 | CN1432012A Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for treatment of pain |
| 07/23/2003 | CN1432011A Benzoamide piperidine compounds as substance P antagonists |
| 07/23/2003 | CN1432007A Inhibitors of alpha L beta 2 mediated cell adhesion |
| 07/23/2003 | CN1431999A Indole derivatives with vascular damagine activity |
| 07/23/2003 | CN1431998A Growth hormone secretagogues |
| 07/23/2003 | CN1431997A 2-acyl indol derivatives and their use as anti-tumour agents |
| 07/23/2003 | CN1431941A 挤压模 Extrusion die |
| 07/23/2003 | CN1431911A Transgenically produced decorin |
| 07/23/2003 | CN1431909A Combinations for treating neoplasms |
| 07/23/2003 | CN1431905A Use of fulvestrant in treatment of resistant breast cancer |
| 07/23/2003 | CN1431902A Therapeutic combinations of antihypertensive and antiangiogenic agents |
| 07/23/2003 | CN1431899A Pharmaceutical combination of bicalutamide and tamoxifen for providing anti-androgenic effect and anti-oestrogenic effect |
| 07/23/2003 | CN1431311A Method for expressing thymopolypeptides šŒ1 by use of escherichia coli and its application |
| 07/23/2003 | CN1431310A Transferring carrier of liver cancer target to ward gene introduced by acceptor of alphafetoprotein enhancement type epidermal growth factor dual controlled by transcription and transfer |
| 07/23/2003 | CN1431305A Reorganization immunity toxin with high specificity and its preparing method |
| 07/23/2003 | CN1431304A Anti blood tumorous reverse VEGF gene sequence and expression carrier of recombination eukaryon |
| 07/23/2003 | CN1431298A Antineoplastic immunocompetent cell-cell of DCIC, its preparing method and applications |
| 07/23/2003 | CN1431217A Human angiogenin antisense oligonucleotide and medicine combination |
| 07/23/2003 | CN1431196A Carotenoid possessing anticancer function and its preparing method |
| 07/23/2003 | CN1431187A Kaurane type diterpene compound and its preparing method as well as application in anticancer drugs |
| 07/23/2003 | CN1431017A Microcapsule meterial for durative releasing two factors for restraining new-born blood vessels and its preparing method |
| 07/23/2003 | CN1431015A Compound fungi medicine for restraining tumors and its preparing method |
| 07/23/2003 | CN1430982A Capsule of astragalus and honey as well as its preparing technique |
| 07/23/2003 | CN1115414C Virus carrier used for gene therapy |
| 07/23/2003 | CN1115342C Hypnotic beta-carboline derivatives, process for their prepn. and their use as medicinal products |
| 07/23/2003 | CN1115330C N-(4-carbamimido-phenyl)-phenylglycinamid derivatives |
| 07/23/2003 | CN1115161C Aitonging plaster for treating cancer and its prepn. method |
| 07/23/2003 | CN1115156C Antisenescence Chinese medicine |
| 07/22/2003 | US6596885 19-Nor steroids having a thiocarbonated chain in position 11beta, their preparation process and the intermediates of this process, their use as medicaments and compositions |
| 07/22/2003 | US6596851 Antibody for use in the treatment of cell proliferative disorders |
| 07/22/2003 | US6596845 Cinnamoyl distamycin analogous derivatives, process for their preparation, and their use as antitumor agents |
| 07/22/2003 | US6596791 Polymer complexes of glucuronoglucanes |
| 07/22/2003 | US6596772 Relates to trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compounds and the physiologically acceptable salts and the prodrugs thereof. These compounds are expected to modulate the activity of protein tyrosine enzymes which are |
| 07/22/2003 | US6596769 20-Hete antagonists and agonists |
| 07/22/2003 | US6596757 Taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more polyethylene glycol-containing taxanes covalently bonded to a cell binding |
| 07/22/2003 | US6596753 Compounds of the indolecarboxylic family and use thereof |
| 07/22/2003 | US6596751 α-substituted carboxylic acid derivatives |
| 07/22/2003 | US6596746 Cyclic protein tyrosine kinase inhibitors |
| 07/22/2003 | US6596738 Inhibiting activity to adenosine deaminase (hereinafter described as ADA) An adenosine deaminase inhibiting agent comprising a compound of the formula (I): |
| 07/22/2003 | US6596737 C10 carbamoyloxy substituted taxanes |
| 07/22/2003 | US6596735 Compounds and to the use of said compounds for inhibiting abnormal cell growth in mammals. The compounds of the above formula have activity as farnesyl protein transferase inhibitors. for treatment of cancer andhyperproliferation |
| 07/22/2003 | US6596732 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same |
| 07/22/2003 | US6596730 Phenyl urea and phenyl thiourea derivatives |
| 07/22/2003 | US6596726 Method of inhibiting epidermal growth factor by treating, with an effective inhibiting amount, a mammal, in need thereof inhibit the epidermal growth factor receptor and related receptors and, in particular, their tyrosine kinase enzyme |
| 07/22/2003 | US6596719 6 alkoxy-4-pyrimidinyl bis-sulfonamides |
| 07/22/2003 | US6596701 S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
| 07/22/2003 | US6596694 Caloporoside derivatives, methods of their preparation and use |
| 07/22/2003 | US6596692 Substance P analogs for the treatment of cancer |
| 07/22/2003 | US6596533 Polypeptide for use in the treatment of infections and cell proliferative disorders |
| 07/22/2003 | US6596503 Diagnosing cancer in humans; obtain tissue sample, incubate with monoclonal antibody, determine presence of antibody-antigen complex, amplified levels of antigen indicates cancer |
| 07/22/2003 | US6596491 Tenascin-C nucleic acid ligands |
| 07/22/2003 | US6596473 Detection of antiapotosis protein; obtain genetically engineered cells, measure viable cells, incubate with antiapoptosis agent, compare with control, evaluate adjustment in apoptosis activity |
| 07/22/2003 | US6596319 Such as various cancers, by administering low molecular weight compounds of following properties: extractable from bile of an animal, stimulates monocytes and macrophages, modulates tumor necrosis factor production, not endotoxin |
| 07/22/2003 | US6596296 Three dimensional matrices for growing cells; controlled delivery of therapeutic agents |
| 07/22/2003 | US6596268 Viruses for the treatment of cellular proliferative disorders |
| 07/22/2003 | CA2269923C Pharmaceutical compositions containing plasma protein |
| 07/22/2003 | CA2045891C Oligonucleotide analogs with terminal 3'-3' or 5'-5' internucleotide linkages |
| 07/17/2003 | WO2003058021A2 Novel apoptosis-inducing dna sequences |
| 07/17/2003 | WO2003057926A1 Gene products differentially expressed in cancerous breast cells and their methods of use |
| 07/17/2003 | WO2003057888A1 Cell-specific expression/replication vector |
| 07/17/2003 | WO2003057887A1 Novel udp-n-acetyl-d-galactosamine:polypeptide n-acetylgalactosamine transferases and nucleic acids encoding the same |
| 07/17/2003 | WO2003057856A2 Dominant negative proteins and methods thereof |
| 07/17/2003 | WO2003057854A2 Novel proteins and nucleic acids encoding same |
| 07/17/2003 | WO2003057838A2 Antibodies against the muc18 antigen |
| 07/17/2003 | WO2003057837A2 Methods for using anti-muc18 antibodies |
| 07/17/2003 | WO2003057835A2 Pak5-related compositions and methods |
| 07/17/2003 | WO2003057829A2 Methods of generating multispecific, multivalent agents from vh and vl domains |
| 07/17/2003 | WO2003057823A2 Epitope synchronization in antigen presenting cells |
| 07/17/2003 | WO2003057822A2 Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| 07/17/2003 | WO2003057730A1 Ligand for g-protein coupled receptor gpr43 and uses thereof |
| 07/17/2003 | WO2003057729A2 Mammal prolactin variants |
| 07/17/2003 | WO2003057726A1 Cytotoxic cyplasin of the sea hare, Aplysia punctata, cDNA cloning and expression of bioreactive recombinants |
| 07/17/2003 | WO2003057722A2 Cyclic tetrapeptide compound and use thereof |
| 07/17/2003 | WO2003057707A1 2-o-( -d-glucopyranosyl)ascorbic acid, process for its production, and foods and cosmetics containing compositions comprising it |
| 07/17/2003 | WO2003057699A1 Dibenzodiazepine derivates, their preparation and use |
| 07/17/2003 | WO2003057696A1 Deazapurines and uses thereof |
| 07/17/2003 | WO2003057690A1 Indolinone derivatives useful as protein kinase inhibitors |
| 07/17/2003 | WO2003057685A1 Luminacin analogs and uses thereof |
| 07/17/2003 | WO2003057676A1 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists |
| 07/17/2003 | WO2003057669A1 Androgen receptor antagonists |
| 07/17/2003 | WO2003057668A1 Nitrogenous cyclic ketone derivative, process for producing the same, and use |
| 07/17/2003 | WO2003057666A2 Inhibitors of dipeptidyl peptidase iv |
| 07/17/2003 | WO2003057250A1 Cancer treatment |
| 07/17/2003 | WO2003057239A1 Polyphenol inhibition of nucleoside diphosphate kinase-b activity and cancer metastasis |
| 07/17/2003 | WO2003057224A1 Apoptosis inductor |
| 07/17/2003 | WO2003057219A1 Aroyl pyrrole heteroeryl and methanols useful for treating a central nervous system disorder |
| 07/17/2003 | WO2003057217A1 Combinations comprising epothilones and anti-metabolites |
| 07/17/2003 | WO2003057214A1 Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands |
| 07/17/2003 | WO2003057212A1 Polyamide derivatives possessing antibacterial, antifungal or antitumor activity |
| 07/17/2003 | WO2003057211A1 Composition inhibiting matrix-metallproteinases for the treatmentof neoplastic diseases. |
| 07/17/2003 | WO2003057208A1 Taxane based compositions and methods of use |
| 07/17/2003 | WO2003057203A2 Biomaterials based on hyaluronic acid for the anti-angiogenic therapy in the treatment of tumours |
| 07/17/2003 | WO2003057201A2 A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer |
| 07/17/2003 | WO2003057196A1 Drug mixture with enhanced dissolution rate |
| 07/17/2003 | WO2003057169A2 4-dedimethylamino tetracycline compounds |
| 07/17/2003 | WO2003057168A2 Cancer-associated epitope |
| 07/17/2003 | WO2003057166A2 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 07/17/2003 | WO2003057163A2 Methods for preparing immunoconjugates |
| 07/17/2003 | WO2003057160A2 Compositions and methods for the diagnosis and treatment of tumor |